DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B | Real-time Bid/Ask 17:00:40 03/07/2024 BST | ||
| 97.5 EUR / 97.53 EUR | -1.28% |
|
| Current month | -0.29% | ||
| 1 month | +2.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 97.65 | -1.14% |
| 02/07/24 | 98.78 | -0.33% |
| 01/07/24 | 99.11 | +0.04% |
| 28/06/24 | 99.07 | +0.03% |
| 27/06/24 | 99.04 | -0.20% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 04:24 pm
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME79EQ |
| ISIN | DE000ME79EQ4 |
| Date issued | 22/01/2024 |
| Maturity | 20/12/2024 (170 Days) |
| Parity | 1 : 1 |
| Emission price | 88.13 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 99.24 € |
|---|---|
| Lowest since issue | 84.65 € |
| Spread | 0.05 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
